Tag Archive for: Qalsody

Europe’s medicines regulator on Friday recommended granting a marketing authorization to Biogen’s drug for the deadly and progressive neurodegenerative disease known as amyotrophic lateral sclerosis (ALS).

The recent FDA approval of Biogen’s Qalsody for superoxide dismutase 1 (SOD1)–ALS highlighted the potential for antisense oligonucleotides in central nervous system diseases. But the recent failure of Wave Life Sciences’ WVE-004 in C9orf72–ALS also showed their limitations.